Skip to content
10-K

Annual Report

REGENEREX PHARMA, INC. RGPX

0001472375-25-000070

← back to feed
Filed
Jun 30, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Jun 30, 2025 281.07M sh
Operating Cash Flow FY 2024 · Mar 31, 2025 −$1.63M
Operating Cash Flow FY 2024 · Mar 31, 2024 −$457.55K
Cash And Equivalents FY 2024 · Mar 31, 2025 $653.03K
Cash And Equivalents FY 2024 · Mar 31, 2024 $372
Stockholders Equity FY 2024 · Mar 31, 2025 −$4.16M
Stockholders Equity FY 2024 · Mar 31, 2024 −$4.06M
Stockholders Equity FY 2024 · Mar 31, 2023 −$1.12M
Current Liabilities FY 2024 · Mar 31, 2025 $4.92M
Current Liabilities FY 2024 · Mar 31, 2024 $3.84M
Total Liabilities FY 2024 · Mar 31, 2025 $5.42M
Total Liabilities FY 2024 · Mar 31, 2024 $4.83M
Current Assets FY 2024 · Mar 31, 2025 $653.38K
Current Assets FY 2024 · Mar 31, 2024 $2.91K
Total Assets FY 2024 · Mar 31, 2025 $1.26M
Total Assets FY 2024 · Mar 31, 2024 $766.68K
Sga Expense FY 2024 · Mar 31, 2025 $1.16M
Sga Expense FY 2024 · Mar 31, 2024 $1.07M
Rd Expense FY 2024 · Mar 31, 2025 $662.48K
Rd Expense FY 2024 · Mar 31, 2024 $2.4M
Net Income FY 2024 · Mar 31, 2025 −$2.53M
Net Income FY 2024 · Mar 31, 2024 −$3.54M
Operating Income FY 2024 · Mar 31, 2025 −$1.83M
Operating Income FY 2024 · Mar 31, 2024 −$3.47M
Long Term Debt FY 2024 · Mar 31, 2024 $184.23K